{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = <nowiki>(2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide</nowiki>
| image = Hexarelin_structure.png
| width = 300

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = [[Intravenous]], [[subcutaneous injection|subcutaneous]], [[intranasal]], [[oral administration|oral]]<ref name="pmid8126144">{{cite journal |vauthors=Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, etal | title=Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. | journal=J Clin Endocrinol Metab | year= 1994 | volume= 78 | issue= 3 | pages= 693–8 | pmid=8126144 | doi=10.1210/jcem.78.3.8126144 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8126144  }}</ref>

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = ~55 minutes<ref name="Imbimbo Mant Edwards Amin 1994">{{cite journal | last=Imbimbo | first=B.P. | last2=Mant | first2=T. | last3=Edwards | first3=M. | last4=Amin | first4=D. | last5=Dalton | first5=N. | last6=Boutignon | first6=F. | last7=Lenaerts | first7=V. | last8=Wďż˝thrich | first8=P. | last9=Deghenghi | first9=R. | title=Growth hormone-releasing activity of hexarelin in humans | journal=Eur J Clin Pharmacol | publisher=Springer Science $\mathplus$ Business Media | volume=46 | issue=5 | year=1994 | url=https://dx.doi.org/10.1007/BF00191904 | doi=10.1007/bf00191904 | accessdate=2015-06-12}}</ref>
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 140703-51-1
| CAS_supplemental = 
| ATC_prefix = None
| ATC_suffix = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 09QF37C617
| PubChem = 6918297
| ChEMBL = 108335	
| IUPHAR_ligand = 1100
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 5293503

<!--Chemical data-->
| C=47 | H=58 | N=12 | O=6
| molecular_weight = 887.04022 g/mol
| smiles = CC1=C(C2=CC=CC=C2N1)C[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC6=CNC=N6)N
|  StdInChI = 1S/C47H58N12O6/c1-27-34(33-15-7-9-17-37(33)54-27)23-41(58-44(62)35(49)22-31-25-51-26-53-31)45(63)55-28(2)43(61)57-40(21-30-24-52-36-16-8-6-14-32(30)36)47(65)59-39(20-29-12-4-3-5-13-29)46(64)56-38(42(50)60)18-10-11-19-48/h3-9,12-17,24-26,28,35,38-41,52,54H,10-11,18-23,48-49H2,1-2H3,(H2,50,60)(H,51,53)(H,55,63)(H,56,64)(H,57,61)(H,58,62)(H,59,65)/t28-,35-,38-,39+,40-,41+/m0/s1
|  StdInChIKey = RVWNMGKSNGWLOL-GIIHNPQRSA-N
| synonyms = <small>L</small>-Histidyl-2-methyl-<small>D</small>-tryptophyl-<small>L</small>-alanyl-<small>L</small>-tryptophyl-<small>D</small>-phenylalanyl-<small>L</small>-lysinamide
}}

'''Examorelin''' ([[International Nonproprietary Name|INN]]) (developmental code names '''EP-23905''', '''MF-6003'''), also known as '''hexarelin''', is a [[potency (pharmacology)|potent]], [[Organic compound#Synthetic compounds|synthetic]], [[peptide|peptidic]], [[oral administration|orally-active]], [[central nervous system|centrally-penetrant]], and highly selective [[agonist]] of the [[growth hormone secretagogue receptor|ghrelin/growth hormone secretagogue receptor]] (GHSR) and a [[growth hormone secretagogue]] which was developed by [[Mediolanum Farmaceutici]].<ref name="GanellinTriggle1996">{{cite book|author1=C.R. Ganellin|author2=David J. Triggle|title=Dictionary of Pharmacological Agents|url=https://books.google.com/books?id=Z_mfTTIApVEC&pg=PA617|date=21 November 1996|publisher=CRC Press|isbn=978-0-412-46630-4|pages=617–}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA117|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=117–}}</ref><ref name="pmid17520591">{{cite journal|vauthors=Moulin A, Ryan J, Martinez J, Fehrentz JA | title=Recent developments in ghrelin receptor ligands. | journal=ChemMedChem | year= 2007 | volume= 2 | issue= 9 | pages= 1242–59 | pmid=17520591 | doi=10.1002/cmdc.200700015 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17520591}}</ref><ref name="pmid19243281">{{cite journal|vauthors=Wang Y, Tomlinson B | title=Tesamorelin, a human growth hormone releasing factor analogue. | journal=Expert Opin Investig Drugs | year= 2009 | volume= 18 | issue= 3 | pages= 303–10 | pmid=19243281 | doi=10.1517/13543780802707658 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19243281}}</ref><ref name="Carpino 2002 pp. 1599–1618">{{cite journal | last=Carpino | first=Philip A | title=Recent developments in ghrelin receptor (GHS) | journal=Expert Opin. Ther. Patents | publisher=Informa Healthcare | volume=12 | issue=11 | year=2002 | pages=1599–1618 | url=https://dx.doi.org/10.1517/13543776.12.11.1599 | doi=10.1517/13543776.12.11.1599 | accessdate=2015-06-12}}</ref> It is a [[hexapeptide]] with the [[amino acid sequence]] His-<small>D</small>-2-methyl-Trp-Ala-Trp-<small>D</small>-Phe-Lys-NH<sub>2</sub> which was derived from [[GHRP-6]]. These GH-releasing peptides have no sequence similarity to ghrelin, but mimic ghrelin by acting as agonists at the [[ghrelin]] receptor.<ref name="pmid17520591" /><ref name="pmid19243281" />

Examorelin substantially and dose-dependently increases [[Blood plasma|plasma]] levels of [[growth hormone]] (GH) in animals and humans.<ref name="Imbimbo Mant Edwards Amin 1994" /> In addition, similarly to [[pralmorelin]] (GHRP-2) and GHRP-6, it slightly and dose-dependently stimulates the release of [[prolactin]], [[adrenocorticotropic hormone]] (ACTH), and [[cortisol]] in humans.<ref name="Imbimbo Mant Edwards Amin 1994" /><ref name="Arvat Vito Maccagno Broglio 1997 pp. 885–891">{{cite journal | last=Arvat | first=Emanuela | last2=Vito | first2=Lidia Di | last3=Maccagno | first3=Barbara | last4=Broglio | first4=Fabio | last5=Boghen | first5=Muni F | last6=Deghenghi | first6=Romano | last7=Camanni | first7=Franco | last8=Ghigo | first8=Ezio | title=Effects of GHRP | journal=Peptides | publisher=Elsevier BV | volume=18 | issue=6 | year=1997 | pages=885–891 | url=https://dx.doi.org/10.1016/S0196-9781(97)00016-8 | doi=10.1016/s0196-9781(97)00016-8 | accessdate=2015-06-12}}</ref> There are conflicting reports on the ability of examorelin to elevate [[insulin-like growth factor 1]] (IGF-1) and [[insulin-like growth factor-binding protein 1]] (IGFBP-1) levels in humans, with some studies finding no increase and others finding a slight yet statistically significant increase.<ref name="Imbimbo Mant Edwards Amin 1994" /><ref name="Ghigo Arvat Gianotti Grottoli 1996 pp. 407–412">{{cite journal | last=Ghigo | first=E | last2=Arvat | first2=E | last3=Gianotti | first3=L | last4=Grottoli | first4=S | last5=Rizzi | first5=G | last6=Ceda | first6=G. | last7=Boghen | first7=M. | last8=Deghenghi | first8=R | last9=Camanni | first9=F | title=Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging | journal=European Journal of Endocrinology | publisher=BioScientifica | volume=135 | issue=4 | year=1996 | pages=407–412 | url=https://dx.doi.org/10.1530/eje.0.1350407 | doi=10.1530/eje.0.1350407 | accessdate=2015-06-12}}</ref><ref name="Laron Frenkel Deghenghl Anin 1995 pp. 631–635">{{cite journal | last=Laron | first=Z. | last2=Frenkel | first2=J. | last3=Deghenghl | first3=R. | last4=Anin | first4=S. | last5=Klinger | first5=B. | last6=Siibergeld | first6=A. | title=Intranasal administration of the GHRP | journal=Clinical Endocrinology | publisher=Wiley-Blackwell | volume=43 | issue=5 | year=1995 | pages=631–635 | url=https://dx.doi.org/10.1111/j.1365-2265.1995.tb02929.x | doi=10.1111/j.1365-2265.1995.tb02929.x | accessdate=2015-06-12}}</ref><ref name="Frenkel Silbergeld Deghenghi Laron 1995">{{cite journal | last=Frenkel | first=J. | last2=Silbergeld | first2=A. | last3=Deghenghi | first3=R. | last4=Laron | first4=Z. | title=Short Term Effect of Intranasal Administration of Hexarelin | journal=Journal of Pediatric Endocrinology and Metabolism | publisher=Walter de Gruyter (GmbH) | volume=8 | issue=1 | year=1995 | url=https://dx.doi.org/10.1515/JPEM.1995.8.1.43 | doi=10.1515/jpem.1995.8.1.43 | accessdate=2015-06-12}}</ref> Examorelin does not affect plasma levels of [[glucose]], [[luteinizing hormone]] (LH), [[follicle-stimulating hormone]] (FSH), or [[thyroid-stimulating hormone]] (TSH) in humans.<ref name="Imbimbo Mant Edwards Amin 1994" />

Examorelin releases more GH than does [[growth hormone-releasing hormone]] (GHRH) in humans,<ref name="Arvat Vito Maccagno Broglio 1997 pp. 885–891" /><ref name="Maccario Arvat Procopio Gianotti 1995 pp. 134–138">{{cite journal | last=Maccario | first=M. | last2=Arvat | first2=E. | last3=Procopio | first3=M. | last4=Gianotti | first4=L. | last5=Grottoli | first5=S. | last6=Imbimbo | first6=B.P. | last7=Lenaerts | first7=V. | last8=Deghenghi | first8=R. | last9=Camanni | first9=F. | last10=Ghigo | first10=E. | title=Metabolic modulation of the growth hormone-releasing activity of hexarelin in man | journal=Metabolism | publisher=Elsevier BV | volume=44 | issue=1 | year=1995 | pages=134–138 | url=https://dx.doi.org/10.1016/0026-0495(95)90300-3 | doi=10.1016/0026-0495(95)90300-3 | accessdate=2015-06-12}}</ref> and produces synergistic effects on GH release in combination with GHRH, resulting in "massive" increases in plasma GH levels even with only low doses of examorelin.<ref name="Massoud Hindmarsh Brook 1996 pp. 4338–4341">{{cite journal | last=Massoud | first=A F | last2=Hindmarsh | first2=P C | last3=Brook | first3=C G | title=Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. | journal=The Journal of Clinical Endocrinology| publisher=The Endocrine Society | volume=81 | issue=12 | year=1996 | pages=4338–4341 | url=https://dx.doi.org/10.1210/jcem.81.12.8954038 | doi=10.1210/jcem.81.12.8954038 | accessdate=2015-06-12}}</ref><ref name="Arvat Vito Gianotti Ramunni 1997 pp. 83–88">{{cite journal | last=Arvat | first=Emanuela | last2=Vito | first2=Lidia Di | last3=Gianotti | first3=Laura | last4=Ramunni | first4=Josefina | last5=Boghen | first5=Muni F. | last6=Deghenghi | first6=Romano | last7=Camanni | first7=Franco | last8=Ghigo | first8=Ezio | title=Mechanisms underlying the negative growth hormone (GH) | journal=Metabolism | publisher=Elsevier BV | volume=46 | issue=1 | year=1997 | pages=83–88 | url=https://dx.doi.org/10.1016/S0026-0495(97)90173-6 | doi=10.1016/s0026-0495(97)90173-6 | accessdate=2015-06-12}}</ref><ref name="Arvat Gianotti Vito Imbimbo 1995 pp. 51–56">{{cite journal | last=Arvat | first=Emanuela | last2=Gianotti | first2=Laura | last3=Vito | first3=Lidia Di | last4=Imbimbo | first4=Bruno P. | last5=Lenaerts | first5=Vincent | last6=Deghenghi | first6=Romano | last7=Camanni | first7=Franco | last8=Ghigo | first8=Ezio | title=Modulation of Growth Hormone-Releasing Activity of Hexarelin in Man | journal=Neuroendocrinology | publisher=S. Karger (AG) | volume=61 | issue=1 | year=1995 | pages=51–56 | url=https://dx.doi.org/10.1159/000126827 | doi=10.1159/000126827 | accessdate=2015-06-12}}</ref> Pre-administration of GH blunts the GH-releasing effect of examorelin, while, in contrast, fully abolishing the effect of GHRH.<ref name="Arvat Vito Gianotti Ramunni 1997 pp. 83–88" /><ref name="Massoud Hindmarsh Brook 1995 pp. 617–621">{{cite journal | last=Massoud | first=Ahmed F. | last2=Hindmarsh | first2=Peter C. | last3=Brook | first3=Charles G. D. | title=Hexarelin induced growth hormone release is influenced by exogenous growth hormone | journal=Clinical Endocrinology | publisher=Wiley-Blackwell | volume=43 | issue=5 | year=1995 | pages=617–621 | url=https://dx.doi.org/10.1111/j.1365-2265.1995.tb02927.x | doi=10.1111/j.1365-2265.1995.tb02927.x | accessdate=2015-06-12}}</ref> Pre-treatment with IGF-1 also blunts the GH-elevating effect of examorelin.<ref name="Owusu-Apenten2010">{{cite book|author=Richard Owusu-Apenten|title=Bioactive Peptides: Applications for Improving Nutrition and Health|url=https://books.google.com/books?id=JJ_MBQAAQBAJ&pg=PA292|date=23 June 2010|publisher=CRC Press|isbn=978-1-4398-1363-8|pages=292–}}</ref> [[Testosterone (medication)|Testosterone]], [[testosterone enanthate]], and [[ethinylestradiol]], though not [[oxandrolone]], have been found to significantly potentiate the GH-releasing effects of examorelin in humans.<ref name="pmid9062497">{{cite journal |vauthors=Loche S, Colao A, Cappa M, Bellone J, Aimaretti G, Farello G, etal | title=The growth hormone response to hexarelin in children: reproducibility and effect of sex steroids. | journal=J Clin Endocrinol Metab | year= 1997 | volume= 82 | issue= 3 | pages= 861–4 | pmid=9062497 | doi=10.1210/jcem.82.3.3795 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9062497}}</ref><ref name="Loche Cambiaso Carta Setzu 1995 pp. 674–678">{{cite journal | last=Loche | first=S | last2=Cambiaso | first2=P | last3=Carta | first3=D | last4=Setzu | first4=S | last5=Imbimbo | first5=B P | last6=Borrelli | first6=P | last7=Pintor | first7=C | last8=Cappa | first8=M | title=The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects. | journal=The Journal of Clinical Endocrinology | publisher=The Endocrine Society | volume=80 | issue=2 | year=1995 | pages=674–678 | url=https://dx.doi.org/10.1210/jcem.80.2.7852535 | doi=10.1210/jcem.80.2.7852535 | accessdate=2015-06-12}}</ref> In accordance, likely due to increases in [[sex steroid]] levels, [[puberty]] has also been found to significantly augment the GH-elevating actions of examorelin in humans.<ref name="Bellone Aimaretti Bartolotta Benso 1995 pp. 1090–1094">{{cite journal | last=Bellone | first=J | last2=Aimaretti | first2=G | last3=Bartolotta | first3=E | last4=Benso | first4=L | last5=Imbimbo | first5=B P | last6=Lenhaerts | first6=V | last7=Deghenghi | first7=R | last8=Camanni | first8=F | last9=Ghigo | first9=E | title=Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty. | journal=The Journal of Clinical Endocrinology| publisher=The Endocrine Society | volume=80 | issue=4 | year=1995 | pages=1090–1094 | url=https://dx.doi.org/10.1210/jcem.80.4.7714074 | doi=10.1210/jcem.80.4.7714074 | accessdate=2015-06-12}}</ref>

A partial and reversible tolerance to the GH-releasing effects of examorelin occurs in humans with long-term administration (50–75% decrease in efficacy over the course of weeks to months).<ref name="pmid9589671">{{cite journal | vauthors = Rahim A, O'Neill PA, Shalet SM | title = Growth hormone status during long-term hexarelin therapy | journal = J. Clin. Endocrinol. Metab. | volume = 83 | issue = 5 | pages = 1644–9 | year = 1998 | pmid = 9589671 | doi = 10.1210/jcem.83.5.4812 | url = http://press.endocrine.org/doi/10.1210/jcem.83.5.4812?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed}}</ref><ref name="Ghigo1999">{{cite book|author=Ezio Ghigo|title=Growth Hormone Secretagogues: Basic Findings and Clinical Implications|url=https://books.google.com/books?id=pDabYbzcGSQC&pg=PA178|year=1999|publisher=Elsevier|isbn=978-0-444-82933-7|pages=178–}}</ref>

Examorelin reached [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s for the treatment of [[growth hormone deficiency]] and [[congestive heart failure]] but did not complete development and was never marketed.<ref name="pmid19243281" /><ref name="pmid4">{{cite journal|vauthors=Wiesmann UN, DiDonato S, Herschkowitz NN | title=Effect of chloroquine on cultured fibroblasts: release of lysosomal hydrolases and inhibition of their uptake. | journal=Biochem Biophys Res Commun | year= 1975 | volume= 66 | issue= 4 | pages= 1338–43 | pmid=4 | doi= 10.1016/0006-291x(75)90506-9| pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4  }}</ref><ref name="pmid17040192">{{cite journal| author=Suckling K| title=Discontinued drugs in 2005: cardiovascular drugs. | journal=Expert Opin Investig Drugs | year= 2006 | volume= 15 | issue= 11 | pages= 1299–308 | pmid=17040192 | doi=10.1517/13543784.15.11.1299 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17040192  }}</ref>

==See also==
* [[Anamorelin]]
* [[Capromorelin]]
* [[GHRP-6]]
* [[Ibutamoren|Ibutamoren (MK-677)]]
* [[Ipamorelin]]
* [[Macimorelin]]
* [[Pralmorelin|Pralmorelin (GHRP-2)]]
* [[Relamorelin]]
* [[SM-130,686]]
* [[Tabimorelin]]

==References==
{{Reflist|2}}


{{GH/IGF-1 axis signaling modulators}}

[[Category:Ghrelin receptor agonists]]
[[Category:Growth hormone secretagogues]]
[[Category:Hormonal agents]]
[[Category:Peptides]]
[[Category:World Anti-Doping Agency prohibited substances]]
[[Category:Experimental drugs]]